Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer
Journal of Thoracic Disease · 2024-09 · 16 (9) · 6094-6100
DOI: 10.21037/jtd-24-891 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2024-09. Verfasst von Masatsugu Hamaji und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kyoto University, Kyoto, Japan. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) improved the long-term survival outcomes in patients with advanced non-small cell lung cancer (NSCLC), whereas the role of salvage surgery after ICIs was unknown. The object of this study was to investigate characteristics and outcomes of patients who underwent salvage surgery after ICIs.
Methods
Retrospective chart review was performed on the basis of our multi-institutional database in search of consecutive patients who underwent salvage surgery after ICIs for initially unresectable NSCLC between 2016 and 2022. Patient characteristics, intraoperative findings, perioperative outcomes, histopathological findings, progression-free survival (PFS), and overall survival (OS) were investigated.
Results
Fifteen patients with a median age of 71 years were included in the study. The surgical approach was open thoracotomy in 5 and robotic or thoracoscopic surgery in 10 patients. Resection was performed for primary lesions in 8 and metastatic lesions in 7 patients. Postoperative complication was noted in 1 patient with grade 1 phrenic nerve palsy. The median PFS was 47.9 months, and the median OS was not reached. Three-year PFS was 0% in those with metastatic lesions and 87.5% in those with primary lesions (P=0.12).
Conclusions
Salvage surgery after ICIs may be associated with low perioperative morbidity and acceptable long-term outcomes in selected patients. Salvage resection of primary lesions may be associated with more favorable PFS than of metastatic lesions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Kyoto University, Kyoto, Japan.
- Department of Respiratory Medicine, Kyoto University, Kyoto, Japan.
- Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan.
- Department of Thoracic Surgery, Shiga General Hospital, Shiga, Japan.
- Department of Thoracic Surgery, Osaka Red Cross Hospital, Osaka, Japan.
- Department of Thoracic Surgery, Kyoto City Hospital, Kyoto, Japan.
Zitieren
APA
Hamaji, M., Ozasa, H., Sakamori, Y., Terada, K., Yoshizawa, A., Kikuchi, R., Sakaguchi, Y., Sonobe, M., Muranishi, Y., Miyahara, R., Motoyama, H., Omasa, M., & Date, H. (2024). Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer. Journal of Thoracic Disease, 16(9), 6094-6100. https://doi.org/10.21037/jtd-24-891
Vancouver
Hamaji M, Ozasa H, Sakamori Y, Terada K, Yoshizawa A, Kikuchi R, et al. Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer. Journal of Thoracic Disease. 2024;16(9):6094-6100. doi:10.21037/jtd-24-891
BibTeX
@article{Hamaji2024,
author = {Hamaji, Masatsugu and Ozasa, Hiroaki and Sakamori, Yuichi and Terada, Kazuhiro and Yoshizawa, Akihiko and Kikuchi, Ryutaro and Sakaguchi, Yasuto and Sonobe, Makoto and Muranishi, Yusuke and Miyahara, Ryo and Motoyama, Hideki and Omasa, Mitsugu and Date, Hiroshi},
title = {Characteristics and outcomes of salvage surgery after immune checkpoint inhibitor therapy for initially unresectable non-small cell lung cancer},
journal = {Journal of Thoracic Disease},
year = {2024},
volume = {16},
number = {9},
pages = {6094--6100},
doi = {10.21037/jtd-24-891}
}
EUVIMED